Alterity Therapeutics Limited (NASDAQ:ATHE) Sees Significant Growth in Short Interest

Alterity Therapeutics Limited (NASDAQ:ATHE) saw a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 167,300 shares, a growth of 12.6% from the December 31st total of 148,600 shares. Based on an average daily trading volume, of 64,600 shares, the short-interest ratio is currently 2.6 days. Currently, 2.0% of the company’s shares are sold short.

Alterity Therapeutics Stock Down 1.0 %

Shares of Alterity Therapeutics stock traded down $0.05 on Monday, hitting $4.75. The company had a trading volume of 396,110 shares, compared to its average volume of 1,333,451. Alterity Therapeutics has a twelve month low of $1.00 and a twelve month high of $5.87. The stock has a 50-day moving average of $2.78 and a 200-day moving average of $1.83.

Hedge Funds Weigh In On Alterity Therapeutics

An institutional investor recently raised its position in Alterity Therapeutics stock. HB Wealth Management LLC grew its position in Alterity Therapeutics Limited (NASDAQ:ATHE) by 34.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 31,883 shares of the company’s stock after purchasing an additional 8,100 shares during the period. HB Wealth Management LLC owned approximately 0.44% of Alterity Therapeutics worth $110,000 at the end of the most recent quarter. 2.14% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Maxim Group lifted their target price on Alterity Therapeutics from $8.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday. Benchmark cut Alterity Therapeutics from a “speculative buy” rating to a “hold” rating in a report on Monday.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.